2m 2m 2m 2m 2m 2m 2m
CANDEL THERAPEUT (CADL)
NASDAQ
$8.93+$0.51 (+6.00%)
Price as of Jun 03, 2026 7:59 PM EDT- $608.1MMarket Cap
- 46.43%1-Year Change
- BiotechnologyIndustry
CANDEL THERAPEUT (CADL)
$8.93+$0.51 (+6.00%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | N/A N/A | N/A N/A | 125,000 0.00% | 125,000 0.00% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 -100.00% | 125,000 0.00% | 125,000 0.00% | |
Sales and Marketing Expense | 14.7M +183.64% | 5.2M N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -30.5M +57.90% | -19.3M -21.19% | -24.5M +17.89% | -20.8M +36.95% | |
Depreciation and Amortization Expense | 845,000 -14.65% | 990,000 +3.13% | 960,000 +23.39% | 778,000 +235.34% | |
Total Operating Expenses | 48.3M +44.63% | 33.4M -13.08% | 38.4M +10.17% | 34.8M +34.80% | |
Operating Profit | -48.3M +44.63% | -33.4M -13.08% | -38.4M +10.57% | -34.7M +34.97% | |
Interest Income | 3.9M +260.50% | 1.1M -47.81% | 2.1M N/A | N/A N/A | |
Interest Expense | -2.1M +1.39% | -2.1M -19.46% | -2.6M +62.19% | -1.6M N/A | |
Interest Income and Expense and Net | 1.8M +278.88% | -1.0M +95.33% | -514,000 -67.87% | -1.6M N/A | |
Total Nonoperating Income and Expense | 10.1M +146.24% | -21.8M -4,924.34% | 452,000 -97.16% | 15.9M +253.18% | |
Income before Taxes | -48.3M +44.63% | -33.4M -13.08% | -38.4M +10.57% | -34.7M +34.97% | |
Income Taxes | 0 N/A | 0 N/A | 0 N/A | 0 N/A | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -38.2M -30.80% | -55.2M +45.44% | -37.9M +101.87% | -18.8M -47.97% | |
Net Income from Continuing Operations Applicable to Common | -38.2M -30.80% | -55.2M +45.44% | -37.9M +101.87% | -18.8M -47.97% | |
Basic EPS and Net Income | -0.72 -58.62% | -1.74 +32.82% | -1.31 +101.54% | -0.65 -65.97% | |
Diluted EPS and Net Income | -0.72 -58.62% | -1.74 +32.82% | -1.31 +101.54% | -0.65 -65.97% | |
Basic Weighted Average Shares | 53.0M +67.19% | 31.7M +9.47% | 28.9M +0.39% | 28.8M +52.72% | |
Diluted Weighted Average Shares | 53.0M +67.19% | 31.7M +9.47% | 28.9M +0.39% | 28.8M +52.72% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 119.7M +16.64% | 102.7M +189.88% | 35.4M -49.45% | 70.1M -15.23% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 119.7M +16.64% | 102.7M +189.88% | 35.4M -49.45% | 70.1M -15.23% | |
Total Current Assets | 121.4M +16.94% | 103.8M +182.10% | 36.8M -48.85% | 71.9M -15.30% | |
Accumulated Depreciation | 3.6M +15.67% | 3.1M +47.25% | 2.1M +85.03% | 1.1M +220.74% | |
Property and Plant and Equipment and Net | 1.6M -25.06% | 2.2M -31.66% | 3.2M -27.53% | 4.4M +15.33% | |
Total Long-Term Assets | 87,000 +38.10% | 63,000 -45.69% | 116,000 -97.38% | 4.4M +943.40% | |
Total Assets | 125.2M +17.15% | 106.9M +159.38% | 41.2M -46.97% | 77.7M -12.91% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | 0 -100.00% | 9.9M +11.27% | 8.9M N/A | N/A N/A | |
Total Current Liabilities | 9.0M -76.03% | 37.5M +164.59% | 14.2M +152.61% | 5.6M +4.72% | |
Total Long-Term Debt | 47.1M +1,710.60% | 2.6M -78.98% | 12.4M -40.61% | 20.9M +3,623.21% | |
Total Long-Term Liabilities | 1.5M +280.34% | 407,000 -63.56% | 1.1M -55.74% | 2.5M +59.85% | |
Total Liabilities | 73.3M +80.75% | 40.5M +42.46% | 28.5M -5.07% | 30.0M +19.58% | |
Retained Earnings | -230.4M +19.87% | -192.2M +40.27% | -137.0M +38.29% | -99.1M +23.41% | |
Total Stockholders Equity | 51.9M -21.72% | 66.3M +420.42% | 12.7M -73.29% | 47.7M -25.61% | |
Total Shares Outstanding | 54.9M +17.28% | 46.8M +60.91% | 29.1M +0.59% | 28.9M +0.80% | |
Cash Flow | |||||
Cash from Operating Activities | -38.3M +41.77% | -27.0M -21.09% | -34.2M +8.99% | -31.4M +41.41% | |
Capital Expenditures | 587,000 +3,568.75% | 16,000 -96.50% | 457,000 -64.76% | 1.3M -29.32% | |
Cash from Investing Activities | -560,000 +3,400.00% | -16,000 -94.29% | -280,000 -78.41% | -1.3M -29.32% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 56.1M -40.50% | 94.3M +78,017.36% | -121,000 -100.61% | 20.0M -72.18% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | -30,712.80% +10.57% | -27,777.60% N/A | |
Return on Assets | -32.91% -55.85% | -74.53% +16.78% | -63.82% +183.37% | -22.52% N/A | |
Return on Equity | -64.58% -53.73% | -139.56% +11.20% | -125.50% +273.46% | -33.61% N/A | |
Revenue Growth | N/A N/A | N/A N/A | 0.00% N/A | 0.00% N/A | |
Current Ratio | 13.49 +387.79% | 2.77 +6.62% | 2.59 -79.75% | 12.81 N/A | |
Cash Ratio | 13.31 +386.52% | 2.74 +9.56% | 2.50 -79.99% | 12.48 N/A | |
Debt-to-Equity Ratio | 0.91 +381.79% | 0.19 -88.71% | 1.67 N/A | N/A N/A | |
Debt-to-Assets Ratio | 0.38 +221.79% | 0.12 -77.34% | 0.52 N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow